Larimar Therapeutics (LRMR) Other Operating Expenses (2019 - 2020)

Larimar Therapeutics (LRMR) posted Other Operating Expenses of -$10000.0 for Q1 2020, up 97.57% on a QoQ basis from -$411000.0 in Q4 2019.

Larimar Therapeutics (LRMR) Other Operating Expenses (2019 - 2020) Analysis & Trends

Larimar Therapeutics' Other Operating Expenses history runs 2 years deep, the most recent figure standing at -$10000.0 for Q1 2020.

Quarterly Other Operating Expenses changed N/A year-over-year to -$10000.0 in Q1 2020, while the trailing twelve-month figure through Dec 2020 was -$10000.0 (up 99.77% YoY) and the FY2019 annual result came in at -$5.6 million, changed N/A from the prior year.
Other Operating Expenses was -$10000.0 for Q1 2020 at Larimar Therapeutics, up from -$411000.0 in the prior quarter.
Across five years, Other Operating Expenses topped out at -$10000.0 in Q1 2020 and bottomed at -$4.0 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,981.90 Bn	66,981.62 Bn	-
2	Nanobiotix	1,913.50 Bn	1,913.44 Bn	-
3	Akari Therapeutics	959.56 Bn	959.56 Bn	-
4	BeOne Medicines	472.03 Bn	467.24 Bn	1.35 Bn
5	Vertex Pharmaceuticals	122.09 Bn	114.84 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	70.01 Bn	61.26 Bn	3.31 Bn
7	Belite Bio	62.34 Bn	62.34 Bn	-
8	Argenx Se	55.99 Bn	50.80 Bn	1.41 Bn
9	Alnylam Pharmaceuticals	37.49 Bn	34.48 Bn	959.66 Mn
10	Larimar Therapeutics	36.52 Mn	-100.33 Mn	-

Download Data